Stage III NSCLC

Questions discussed in this category

How do you chose between neoadjuvant chemotherapy alone vs neoadjuvant chemoradiation in patients with potentially resectable stage III NSCLC who are not upfront surgical candidates?

1 Answer available

How do you approach elderly patients with stage III NSCLC who have a reasonable performance status?

Do you recommend or make any modifications in the PACIFIC regimen for patients > 75 years of age?

1 Answer available

How do you monitor response for stage III NSCLC patients receiving consolidation immunotherapy?

CT or PET? If so, how often?

3 Answers available

How do you manage pneumonitis in patients with Stage III NSCLC receiving durvalumab?

How do you prescribe a steroid taper? If it is grade 2, would you keep them on low dose prednisone while continuing? When do you feel comfortable re-c...

2 Answers available

How do you time re-staging studies and adjuvant durvalumab for stage III NSCLC treated with definitive cCRT?

Do you feel it is important to start durvalumab within 14 days of completing cCRT? What real life challenges do you face in doing so and wh...

1 Answer available

Do you recommend adjustment of lung dose constraints in the setting of stage III lung cancer treated with definitive concurrent chemoradiation followed by planned consolidation immunotherapy?

3 Answers available

Do you stop consolidative durvalumab after one year as per the PACIFIC trial or continue if the patient is otherwise tolerating well?

1 Answer available

Papers discussed in this category

Lancet (London, England), 2009-08-01

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.

Lung Cancer,

Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature.

Lancet Oncol., 2008 Jun 24

Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer.

The New England journal of medicine, 2018-12-13

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

JAMA oncology, 2019-07-01

N Engl J Med, 2017 Nov 16

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Stage III NSCLC

Questions discussed in this category

Papers discussed in this category

Related Topics